Welcome to ImaginAb
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments.ImaginAb's platform technology enables the rapid antibody engineering for formats that are optimal for diagnostic imaging including the "minibody" and certain optimized forms of diabody. Variable regions attached to these small protein scaffolds retain the binding affinity and specificity of the parental intact antibody while exhibiting pharmacokinetic properties that are optimal for imaging with a radiolabel with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT). We have successfully demonstrated conversion of a variety of well-known therapeutic antibodies into preclinical imaging agents the proof-of-concept of a minibody imaging agent has been demonstrated in the clinic1,2.
Our Mission is Twofold
- Provide antibody-based imaging agent services for biopharma (on a selective basis) to accelerate their development, implementation, and clinical practice of therapeutic antibodies. We view this as an important partnership in order to establish the importance of both antibody imaging in drug discovery and development, but imaging overall – particularly PET.
- Develop promising antibody-based imaging agents against targets for disease indications which are poorly diagnosed by today's standard nuclear medicine/PET procedures. Our objective is to take promising targets through regulatory approval as "qualified biomarkers" (eIND/IND) and "validated biomarkers" (registration) in order to improve patient care.
News
September 23, 2009
The World Molecular Imaging Conference opens in Montreal. ImaginAb will be exhibiting its new line of targeted antibodies for preclinical imaging applications.
More Inf
September 17, 2009
ImaginAb is invited to present at the 11th annual SoCalBio Investor and Partnership Conference.
More Inf
July 1, 2009
Dr. Dan Shochat, Ph.D joins the ImaginAb Scientific Advisory Board and brings with him enormous experience of the antibody radioconjugate world - such as 55Ci scale-up of Bexxar and the development of Mylotarg, the first antibody-cytotoxic drug conjugate to receive FDA marketing clearance.
March 4, 2009
ImaginAb co-founder Anna Wu gives a talk titled "Antibodies for molecular imaging of cancer" at the 3rd International Symposium on Antibody Engineering and Antibody-based Therapeutics in Taipei, Taiwan
February 23, 2009
ImaginAb to become a member of Southern California Biomedical Council (SoCalBio)
December 19, 2008
ImaginAb proudly sponsors and will be giving a keynote address at the 3rd International Symposium on Antibody Engineering and Antibody-based Therapeutics
More Inf
October 15, 2008
ImaginAb and Momentum Biosciences featured at 4entrepreneur.net
More Info
October 12, 2008
ImaginAb's one year anniversary!
October 9, 2008
Momentum Open House event
2. None of the products or services described on this web page have received marketing clearance by the US Food and Drug Administration (FDA) or equivalent international regulatory authority.